about
Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaBone turnover markers are correlated with total skeletal uptake of 99mTc-methylene diphosphonate (99mTc-MDP).Bisphosphonate-induced osteonecrosis of the jaws: review, clinical implications and case report.Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffoldsMolecular mechanisms of crystallization impacting calcium phosphate cements.Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.Bisphosphonate-based strategies for bone tissue engineering and orthopedic implants.Targeting and delivery of platinum-based anticancer drugs.The Platin-X series: activation, targeting, and delivery.Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.An in vitro assay to measure targeted drug delivery to bone mineral.Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite.Bifunctional Platinum(II) Complexes with Bisphosphonates Substituted Diamine Derivatives: Synthesis and In vitro Cytotoxicity.Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone.
P2860
Q28081996-C51A2BDE-EA70-4D9F-8756-F1C5CC441792Q33424068-A8C796A2-BA4C-4175-A8EC-A28016661665Q33594764-03420220-BFA5-41AF-B50F-D4079A837953Q33742858-3E3A2214-7AF1-4AF8-8EF3-62E64BBFDC4FQ34150056-39F0DA4E-A809-4563-90B2-DC64BB4C841FQ34496410-3923A7CD-D324-4121-846F-0542BE824515Q35954529-583D8324-AC93-42B3-963D-46769DEDD65BQ37197298-83C17CFF-868C-4EF9-9499-76E528754E26Q37430269-F80523DA-04C2-47DA-9C25-6C515461FCF4Q37996117-CB7C3AD5-88C3-43FE-B8CD-C42BC2EDA07CQ38050063-5EF149E2-4F6B-4541-B078-DE7B74C9BE91Q38919253-7C15B0D4-879F-497B-ADF1-E026404A2FE2Q39538285-DA8FABBF-9367-40DD-9452-7C8F2E54E0A6Q43139881-2297B081-75C1-4D99-AC30-850176B17963Q47368791-48C22FD8-E570-446C-99E7-103A20ABB7BAQ47603642-F8CAE067-36CD-4537-9359-274D44DDB5C3Q51873934-9A020442-A328-4DF4-929F-FA0C369660CAQ53064404-57E0E3FD-F2BD-4DED-BFA8-F2F83D4F2923
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Bisphosphonate actions: physical chemistry revisited.
@ast
Bisphosphonate actions: physical chemistry revisited.
@en
type
label
Bisphosphonate actions: physical chemistry revisited.
@ast
Bisphosphonate actions: physical chemistry revisited.
@en
prefLabel
Bisphosphonate actions: physical chemistry revisited.
@ast
Bisphosphonate actions: physical chemistry revisited.
@en
P1433
P1476
Bisphosphonate actions: physical chemistry revisited.
@en
P2093
Socrates E Papapoulos
P304
P356
10.1016/J.BONE.2006.01.141
P577
2006-02-28T00:00:00Z